- AVCJ Goes hybrid
- China Webinar
- Contact Us
Senior Industry Professionals include
An error occurred trying to play the stream. Please reload the page and try again.Close
Mr. Wu currently serves as Head of China and Joint Head of Enterprise Development Group. He also undertook the role of Joint Head of Portfolio Strategy & Risk Group at Temasek. Temasek has been actively participating and supporting China’s economic reform and opening-up journey over the past two decades. Temasek invests widely across all stages and all sizes of an enterprise, from early stage disruptors to more mature sectoral champions. As a forward-looking institution, Temasek takes on a long-term investment horizon. China is one of Temasek’s top two largest geographical exposure alongside Singapore, at 29% of the total portfolio or around RMB441b (as at 31 March 2020).
Mr. Wu was previously President of CITIC Private Equity Funds Management, a position he held since December 2009. He concurrently served as Chairman and Chief Executive Officer of Goldstone Investment Co. Ltd., the direct investment arm of CITIC Securities. Mr. Wu began his career with McKinsey, rising to become Senior Partner and Head of Asia Pacific M&A Practice. He was also General Manager of McKinsey Beijing, where he was responsible for providing M&A, corporate restructuring and IPO advisory for large Chinese enterprises. He had advised a number of leading Asian companies in their international expansion effort. He subsequently joined the Lenovo Group, and led the acquisition and integration of the IBM PC business, serving as Chief Strategy Officer, Chief Integration Officer, Chief Transformation Officer/ Chief Information Officer of Lenovo Group.
Mr. Wu was later appointed to Lenovo parent Legend Holdings, as Executive Vice President responsible for the overall business operations and overseeing its direct investment business. Since Nov 2019, Mr Wu has been Board Member of Gavi, the Vaccine Alliances. Mr. Wu serves on the board of China Social Entrepreneur Foundation. Mr. Wu holds a Doctor of Philosophy degree (PhD) in Biochemistry from Harvard University and a Bachelor of Science degree (BSc.) in Molecular Biology from University of Science and Technology of China (1985-1989).
Kurt became Managing Partner of Permira in 2021, having been a Co-Managing Partner since 2008. He serves on the Permira Holdings Limited Board, the Executive Committee, the Firm Operations Committee, the Portfolio Review Committee, the Permira Growth Opportunities Investment Committee and co-chairs the main funds Investment Committee. Kurt joined the London office in 1996 and became a Partner in 2001. From 2003 to 2008 he was responsible for the Nordic office. Kurt has been involved in a number of transactions including AU System, Inmarsat and TDC. He currently serves on the board of English One Limited.
Prior to joining Permira, Kurt worked for Boston Consulting Group in Stockholm.
Kurt has a degree in Economics from SSEBA, Finland, and an MBA from INSEAD, France. He has also completed graduate studies at the Rensselaer Polytechnic Institute in New York, USA.
Jacob Chiu is a Managing Director responsible for Asian PE manager research and co-investments for HQ Capital, a leading global independent alternative investment manager with $8 billion AUM in private equity. Previously, he was a Partner with FLAG Squadron Asia; a Managing Director with Search Investment Group; and held senior operating and financial roles with Glaxo, Kraft and TigerPack. He holds an MSc in Financial Management from the University of London.
Alex Emery is Head of Asia at Permira and also serves on the firm’s Executive Committee. He joined the London office in 2002 and moved to Tokyo to establish Permira’s Japanese presence in 2005, which he led until the end of 2010. Alex has worked on numerous transactions including ABS, Akindo Sushiro, Arysta LifeScience, Cortefiel, Galaxy Entertainment Group, I-MED Radiology Network, Grobest, John Masters Organics, Magento, New Look and Tricor.
Prior to joining Permira, Alex spent five years at McKinsey & Company in London. He was previously at Braxton Associates and began his career at the French Ministry of Foreign Affairs. A French national, Alex has lived in Asia for over 30 years and is a fluent Japanese speaker.
He majored in Political Science and East Asia Studies at Yale University and holds a Master’s degree in European Politics from the College of Europe, Belgium. He also has an MBA from Kellogg Business School, Northwestern University.
Doris is responsible for all aspects of the primary investment process, including fund selection, due diligence, negotiations, monitoring, and general partner relationship management within China.
Prior to joining Adams Street, Doris was a Senior Associate for AdveqInvestment Management Co. Ltd., a global private equity firm, responsible for sourcing and executing growth/buyout funds and secondary investments in China and Japan. Prior to Adveq, Doris focused on direct investment activity for C.V. Starr Investment Advisory Asia Ltd.
Doris was named one of Private Equity International (PEI)’s 40 under 40: Future Leaders of Private Equity. Winners were selected from a field of over 200 nominees based on key qualities such as leadership, innovation, interpersonal skills and technical expertise, among other criteria.
Education: University of Shanghai for Science and Technology, BE
Investment/operational experience: 19 years
Languages: English, Mandarin Chinese
James Huang is Founding Managing Partner of Panacea Healthcare Venture Capital (RMB 870m Fund & USD180.5m Fund). He has devoted his passion diligence、 intelligence and loyalty into life science and investment industry over 30 years. He is a successful entrepreneur, investor and an opinion leader in Venture Capital healthcare sector in China. Panacea Venture is focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Since its inception in 2018, Panacea has three portfolios listed and five more submitted IPO application. Panacea is currently raising its USD Fund II with a target fund size of USD 250 million. James Huang is also managing partner of Kleiner Perkins Caufield & Byers China. He joined the firm in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007. Prior to that, James was a Managing Partner at Vivo Ventures, a Venture Capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). James is Chairman of Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, CASI and Omni Pharmaceuticals. James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.
Mingming has built a strong reputation as an early-stage investor, serial entrepreneur, and engineer. He founded Future Capital Discovery Fund, an early-stage venture fund specializing in enterprise service and high-tech sectors in China, in 2014. He has since established a track record in identifying high potential start-ups and creating industry-leading companies. He was the first institutional investor in Li Auto (NASDAQ: LI) at its angel round, and saw the company grow to more than $23 billion in value. Other “first-check” investments led by Mingming include Niu Technologies (NASDAQ: NIU), Newborn Town (9911.HK), Sensors Data, and Narwal.
Prior to Future Capital, Mingming was an early participant in China’s burgeoning start-up ecosystem both as a serial entrepreneur and angel investor. He built successful companies that were later acquired by Google and Alibaba. He invested in a number of highly successful start-ups including Autohome Inc. (NYSE: ATHM), XD Inc. (2400.HK) and Kujiale. He began his career at Hewlett-Packard, Siebel Systems and PeopleSoft.
Mingming previously served as the Independent Director of Kingsoft Corporation, as well as Board Member for Li Auto and Niu Technologies. Mingming was selected to join the 2021 Forbes Midas Brink List. In 2020, he ranked #55 in Forbes China's Top VC Investors list.
Mingming received a BS in Electrical Engineering from Shanghai Jiaotong University and an MBA from University of Chicago Booth School of Business.
In 2017, Mr. Ji joined Lighthouse Capital and was mainly responsible for the capital market sector and led the fundraising and management of the Lighthouse Growth Fund and several specialty funds. Mr.Ji is also currently the CEO of Wellington Financial Limited
Mr. Ji is previously the Senior Investment Director at YiMei Capital and Vice President at GSR Ventures, and has worked at Global Capital Markets Department of Barclays Capital (New York, Boston)
Mr. Ji studied at the University of New Hampshire and has an MBA degree from Columbia University.
Leading the acquisition of Wellington Financial Limited and concurrently acting as CEO, Mr. Ji is responsible for IPO underwriting and securities business. Previous IPO projects include 360 finance, Qutoutiao, BiliBili and Zhihu
Investment track record of listed companies include：Kuaishou(HK 01024)、 BiliBili(Nasdaq BILI) 、Zhihu（Nasdaq ZH）、Qutoutiao (Nasdaq QTT) 、360 finance (Nasdaq QFIN)、Wanguoshuju (Nasdaq GDS)、Qianxin(SH 688561)
Investment deals include ：Huolala、Poison、Soul、Deepexi、Flash-Ex、Eswin、Guoquan、Spark
Frank Jin is an Executive Director within Morgan Stanley’s Mergers & Acquisitions Department based in Hong Kong. He is currently the M&A Operations Officer for Asia Pacific.
Frank has over 13 years of experience practicing M&A. Prior to joining Morgan Stanley, Frank worked in the Mergers & Acquisitions group at Standard Chartered and the law firm of Sullivan & Cromwell focusing on M&A transactions and leveraged finance in New York and Hong Kong. Frank is dual qualified as a New York lawyer and Hong Kong solicitor.
Frank received a B.Sc. from the University of Toronto, in Biology and Commerce, and a J.D. from Harvard Law School.
Frank’s M&A practice focuses on China-related transactions as well as those involving listed companies in Hong Kong and other venues.
Speaker bio coming soon
Maggie Kwok is the head of our Funds and Regulatory practice group in Asia. She has a broad range of experience spanning from fund formation, downstream investments, capital markets and corporate finance.
Maggie's practice has a particular focus on formation, structuring and maintenance of various types of open ended and close ended funds including hedge funds and private equity funds. She works extensively with hedge fund and private equity managers, family offices, banks, fund administrators, custodians and investors.
Maggie's fluency in the Chinese language (both Putonghua and Cantonese), familiarity with both the Western and Chinese business etiquette and culture, along with her solid training with leading onshore and offshore firms, allow her to tailor her services to meet the needs of clients in this region. She was recognized as one of the top 10 offshore lawyers operating in Asia by Asian Legal Business in 2018 - 2020 and ranked “Highly Regarded” by IFLR 1000 in 2019 - 2021.
Prior to joining the offshore world in 2010, Maggie practised for several years as a Hong Kong lawyer at international law firms including Slaughter and May.
Leong Wai Leng is responsible for the regional management of CDPQ Globalin Asia Pacific. Based in Singapore, she coordinates all CDPQ activities in the region and ensures optimal positioning and outreach. CDPQ has offices in Singapore, New Delhi, Shanghai and Sydney in the Asia Pacific region.
Ms. Leong has over 30 years of experience in the finance and banking sectors, including 13 years in China, where she built a commercial banking business from the ground up. She has an extensive business network in China and in South-East Asia, including in Singapore. Over the course of her career, she has worked in both the buy and sell sides of the industry, in developed and developing financial markets.
Before joining CDPQ in 2018 as Managing Director, Strategic Partnerships, Asia, Ms. Leong was Managing Director and Head of Business Management Unit at the Bank of Singapore, a wholly owned subsidiary of OCBC Bank. Prior to that, she was the Chairman and CEO of OCBC Bank (China). In 2010, she became the first banker from a non-Japanese Asian bank to win a Gold Magnolia Award, one of the highest recognitions from the Shanghai government. Perhaps most noteworthy was the fact it was the Chinese regulatory body, CBRC (Central Banking Regulatory Commission), that nominated her for this award.
Ms. Leong was also Managing Director and Head of Corporate and Institutional Banking at HSBC China. Previously, she held senior positions at multinational corporations such as Philips Electronics China Group, as well as at JP Morgan Bank and at Citibank, in Singapore.
Qingru is a Director at ACP, covering fund and co-investments across the entire APAC region. Prior to joining ACP in 2010, Qingru worked at the Government of Singapore Investment Corporation (Special Investments), where he was an Associate. Qingru holds a BBA in Finance from the University of Michigan, Stephan M. Ross School of Business.
Min Lin is a founding partner of NewQuest and leads the firm’s Greater China business. Min has nearly 20 years’ experience in finance and principal investing in the United States and Asia. Prior to NewQuest, she was a Director focusing on China investments for Bank of America’s Asia Private Equity Group based in Hong Kong.
Prior to relocating to Hong Kong, Min worked for several years at Merrill Lynch in New York within the structured finance group. She has also previously worked as an accountant for Arthur Andersen in China.
Min received her MBA from the MIT Sloan School of Management in Cambridge, MA and an undergraduate degree from Lingnan (University) College of Sun Yat-Sen University in Guangzhou, China. Min studied in the EMBA program of Cheung Kong Graduate School of Business in Beijing. She is a Chartered Financial Analyst. Min currently serves on the Board of Trustees of Lingnan (University) College of Sun Yat-Sen University. Min is fluent in English, Cantonese and Mandarin.
Ms. Liu is the founding partner at Green Harbor Investment, a private equity fund that focuses on Consumer / Retail, TMT and Healthcare sectors. Since Green Harbor’s inception in 2015, Ms. Liu has led the investments in all of Green Harbor’s portfolio companies. Notable recent transactions include buyout of Jason Wu, investments in GymAngel, HomeLink, Wuxi Pharmatec, Sanli Education Group, ZhongAn, Urbaser, Tencent Music Entertainment, Ant Financial, Suning Finance, Three Gorges New Energy, etc.
Prior to founding Green Harbor, Ms. Liu was a private equity investment professional at Yunfeng Capital, responsible for investment analysis, portfolio management and fund raising activities. Key investments include Xiaomi, Youku Tudou, Ali Health Information Technology and Gold Mantis Construction Decoration.
Ms. Liu served as the Acting CFO of PPStream during 2013 and led the Company's sale to Baidu. Prior to that, Ms. Liu was part of the Mergers & Acquisitions team at Deutsche Bank’s investment banking division and completed cross-border buyout transactions in several industries, including AIA’s acquisition of ING’s Asian business and China State Construction International’s acquisition of Far East Global Group, among others.
Ms. Liu graduated from Duke University with a B.S. degree in Economics and is currently enrolled in the “Financial CEO Program” at Tsinghua PBCSF EMBA School.
Recipient of China’s F40 Prominent Young Investor, China’s Best Female Investor, China’s Most Popular Female Investor, etc.
Sean has over 20 years of healthcare and private equity investment experience. At CBC, Sean serves on the firm’s Investment Committee and Management Committee, and leads CBC’s global investment activities in MedTech, IVD and Medical Services. Prior to joining CBC, he was the President of Fosun Private Equity, where he managed over US$1.5bn private equity investment, with a focus on healthcare and cross-border transactions. Prior to Fosun, he was the Head of China and Managing Director for Carlyle Asia Growth Partners, managing over US$2.5bn, leading the firm’s investments in growth and buyout transactions in healthcare and consumer sectors. Previously, Sean was Managing Director of Temasek China, among other private equity investment roles.
Sean holds an MBA from University of Chicago Booth School of Business with High Honors, a Master’s Degree in Biochemistry from University of Utah, and a Bachelor’s Degree in Biology from University of Science and Technology of China.
Danaher Corporation, Vice President, Corporate Development, Head of M&A Asia, Member of DHR China Board (2011 to now).
General Electric China, Director, Business Development ( 2009 to 2011)
McKinsey & Company, Corporate Finance, Asia, Senior Engagement Manager (2004-2009)
Prior to McKinsey, I worked in Deutsche Bank and Merrill Lynch in Asia and North America
Mrs. Sun obtained her Master’s Degree in International Economic Law from the Suzhou University in Jiangsu China.
Mrs. Sun is currently serving as Executive Partner at GIG with 10 years’ investment experience. She has lead and successfully executed Investment Projects with an estimated value of over 100 Million RMB working with International and Top Chinese healthcare companies such as: VivaBiotech(01873), LifeRiver Biology(688317), ARSMO Cosmetic Hospital(430335), Xinbai Medicine(300294), Shanxi Ark Pharmacy(002513) , American-Sino Hospital, Wellem Hospital, Royal Biology, etc.
Jeffery Tang, president of United Value Capital, a healthcare-focused private equity investment fund.
Mr Tang has many years of experience in venture capital and private equity investment in both China and the Silicon Valley, and has led dozens of investments in the new economy, including Xiaomi, Tencent Music Entertainment, JD Health, JD logistics, Will Semiconductor, Haidilao and Qi An Xin Technology etc.
As a founding shareholder of China Music Corporation, Mr Tang co-led the acquisition of Kugou Music and Kuwo Music and their merger with Tencent Music Entertainment (TME) to form the world’s largest music streaming platform with a market value of approximately US$30 billion.
In the healthcare sector, Mr Tang has led the investments in leading digital-healthcare companies, such as JD Health, WeDoctor and Medlinker. He is also the largest shareholder of the pioneering hospital group New Journey, which now owns 100+ medical facilities with over 20,000 hospital beds.
Jeffery graduated from Stanford University, Yale University and Peking University.
Oscar is the Director of APAC Business Development at InCloudCounsel, leading the company’s growth and market entry in the region. Prior to InCloudCounsel, Oscar was a corporate lawyer at Ropes & Gray LLP, focusing on technology M&A and intellectual property transactions. Earlier, Oscar worked as a Google Public Policy Fellow in Washington, DC. Oscar holds a J.D.from the USC Gould School of Law and a M.Sc. from the London School of Economics. He is admitted to the State Bar of California.
Shengzu Wang, Ph.D., CFA, is co-head of Investment Strategy Group Asia of Goldman Sachs Consumer and Investment Management Division. He is responsible for China and EM Asia macro strategies and tactical asset allocation. Prior to GS, he was a senior economist covering China and Hong Kong at Barclays Investment Bank. Shengzu started his economist career in 2009 at the International Monetary Fund (IMF) via its prestigious Economist Program. Since then, he worked on a number of IMF surveillance and lending programs covering advanced and EM economies in Asia Pacific, Africa, and Europe, including being a member of the IMF Greece team in the European Troika in 2014. He also held academic positions at Fudan University and the University of Hong Kong. Shengzu received his Ph.D. in Economics from McGill University, and an M.A. in Economics from the University of British Columbia.
Gian-Marc Widmer is Director and Head of International M&A at CITIC Securities. He joined the firm in 2014 and is focusing on sourcing and execution of cross-border transactions involving Chinese investors/targets.
Based in Beijing, he has been focusing on M&A, restructuring and corporate development since 2001 with a track record of more than US$15bn of transactions executed in Europe, Asia, North+South America.
Completed transactions include USD 400m sale of Brazilian telecom operator Embratel, USD 1.2bn restructuring of Canadian media group Hollinger, USD 10bn restructuring of Eurotunnel, sale of EUR 200m Inner Mongolian wind projects to China Guangdong Nuclear, EUR 1.3bn public takeover of Biotest by Creat, EUR 120m acquisition of German Duerr Ecoclean by Shenyang SBS, sale by Publicis of China subsidiary Genedigi, acquisition of Yinlu from Nestle etc.
Mr. Widmer has previously worked at Lazard in London and New York focusing on transactions including M&A and debt restructuring as well as at Altira Group in their renewable energy fund as head of the China investment team.
Mr. Widmer has been based in China since 2005, holds an MBA from INSEAD and speaks Chinese.
Previously she spent 7 years in NetEase (NASDAQ:NTES) and established its mobile internet business division. As the founder of NetEase news app, Ms. Xu increased the app’s user number from zero to 400 million. She also played a crucial role in establishing the NetEase Open Course.
In 2015, Anna Xu co-founded HIKE Capital with Mark Yang, focusing on the new consuming market and technology innovation. She led investments in CARS Group, FlashEx, IDEAL ONE, RELX, Shimo, Huohua.
Graduated from Nanjing University and China Europe International Business School (CEIBS)
Ms. Jeacy Yan is a Founding Partner of Being Capital, a newly established GP focused on consumer sector investments. Before founding Being Capital in 2021, she was the consumer team head and partner at IDG Capital. Ms Yan has regularly been named in various industry magazines as one of the top and most influential investors in the new consumer sector. She was named as China’s Top 10 New Consumer Investors in 2017 and 2018 by 36Kr, and has been on China’s Top 15 Women Venture Investors as reported by Forbes China on its 2020 and 2021 “Midas List” of successful VC investors. She was most recently included as one of the “2021 China Top 20 Women Direct Investment Fund Investors” by the China Fund of Funds Alliance. Prior to joining IDG Capital, Ms. Yan worked for Deutsche Bank in Hong Kong and was involved in multiple pre-IPO fund raisings, IPOs and secondary transactions. Ms. Yan also worked for the bond trading department at WestLB in New York. Ms. Yan holds dual Master’s Degrees in Electrical Engineering and Industrial Engineering & Management Science at Northwestern University and dual Bachelor’s Degrees in Electronics and Economics at Peking University.
Speaker bio coming soon
Zhan is an Investment Principal responsible for origination and execution, and is based in the firm’s Hong Kong office.
Prior to joining Coller Capital in 2016, Zhan was a Director at BlackRock Private Equity Partners. Previously, he worked at Swiss Re Private Equity Partners and Adveq Management in Zurich, Beijing and Hong Kong.
Zhan has a BEng in Environmental Engineering from Tianjin University, an MSc in Environmental Science from Nanyang Technological University and an MBA from INSEAD. Zhan is a CFA Charterholder.
Jinjian Zhang is the founding Partner of Vitalbridge. Established in Oct 2019, Vitalbridge focuses on scientific and technological services in education, healthcare, and enterprise services from “demographic structure” and “technological innovation” perspectives aiming to support the upgrade of “New Service” enabled by technologies.
Jinjian Zhang led the investments including Puxin (NY:NEW), Jiliguala, Liulishuo (NY:LAX), Cloopen (NY:RAAS), Kaishu Story, Unisound, Dustess, Maycur and etc.
Jinjian Zhang graduated with his Master degree from Fudan University National Laboratory of Artificial Intelligence and Image.
Mr. Zhao founded InnoVision Capital (known as the “Firm”), in 2016. Mr. Zhao sits on the investment committee of the Firm and is responsible for sourcing proprietary investment opportunities and overseeing execution of new investments and exits as well as the Firm itself.
Mr. Zhao also acts as the primary partner where he serves as the head of portfolio companies’ management committees, in addition to serving on their boards, and leads the close monitoring of their operational and financial performance.
Prior to Founding InnoVision Capital, Mr. Zhao was a Director at KKR Asia where he spent over 10 years, responsible for investments in the consumer, service and technology sector in Greater China. Mr. Zhao started his career at Morgan Stanley Private Equity Asia.
Mr. Zhao earned a B.A. in Mathematics and Physics from Tsinghua University.
Wei Zhou is the Founding Managing Partner at CCV. Before starting CCV, Wei was Managing Partner at KPCB China as a founding member and led its digital practice group in Greater China where he started his VC career.
Leading the top-tier Silicon Valley VC China fund for 10 years, Wei backed companies at early stage including JD.com (NASDAQ: JD), CreditEase (NYSE: YRD), Rong360 (NYSE: JT), Himalaya FM, Yixia.com, Tan Tan (acquired by NASDAQ: MOMO), VenusTech (SZ: 002439), Manzuo.com (acquired by SuNing), ULUCU (NEEQ: 837110), Miaozhen Systems (Mininglamp Technology), Asia Innovation Group, Scinor Water (acquired by TRCE: 300332), KJY Water (NEEQ: 835159), and Arrail Dental. After establishing CCV, Wei invested JD Digits, Shukun Technology, Yunhu Health, Dingdong Class, Perfect, Ice Kredit, Zuzuche, Veer VR, Menya, Joyrun, and Cowa Robot. Wanka Onlinewent public less than 18 months after CCV’s series B investment.
CCV has successfully raised over $520 million in USD funds and 1.5 billion in RMB funds since its launch in 2017. It has also reaped an excellent result of 2 IPO portfolio, Wanka Online (SEHK: 1762), which was listed on the HKSE within 18 months after CCV's investment. New material sector portfolio Q&C silicon Co., LTD landed on the main board of SSE (Shanghai Stock Exchange).
Before joining KPCB China, Wei was the CEO of Shanghai Hanbo Tech Co., a leading e-payment solution provider, which was later successfully acquired. Prior to that, Wei held senior positions at Start Computer Group (SHSE:600734) since 1994. As the youngest executive, he grew from a regional operation leader to the supervisor of the entire e-payment ecosystem and corporate M&A. He led the company throughout its startup stage, IPO, to the following years of fast growth.
Wei has been named among China’s Top 30 Venture Capitalists by Forbes China for four consecutive years. Wei has been honored as Top 30 Most Influential Investors of the Year by Fortune, China’s Top 10 Venture Capitalist by CV Awards, China’s Top 10 Influential Investors by China Renaissance, and China’s Top 50 Founding Partners Voted by Fund of Funds by FoF Weekly.
Wei serves as treasurer of China Venture Capital and Private Equity Association (“CVCA”). Wei holds an M.B.A. from the Wharton School of the University of Pennsylvania and bachelor’s degree in Engineering from the University of Electronic Science and Technology of China.
Jielun Zhu earned his MBA from Harvard Business School with distinction and B.A. degree with honors from Wesleyan University. He is also a CFA charter holder.
Mr. Zhu has over 15 years of experience working across investment banking and strategy consulting for global and regional healthcare clients.
Immediately prior to joining I-Mab, Mr. Zhu was Managing Director and Asia Head of Healthcare Investment Banking and Capital Markets in Hong Kong for Jefferies Group LLC. At Jefferies, he led many high-profile IPO, M&A and other strategic transactions for biotechnology and other healthcare clients in the Greater China region and beyond. Before Jefferies, he worked for Deutsche Bank in its Hong Kong office as a senior member of the healthcare coverage team and for UBS AG in Hong Kong prior to that. Before investment banking, Mr. Zhu was a strategy consultant in Boston serving clients in the pharmaceutical and biotechnology industry in the U.S.